Compare CDLX & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDLX | ADVB |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1M | 8.6M |
| IPO Year | 2018 | 2023 |
| Metric | CDLX | ADVB |
|---|---|---|
| Price | $1.27 | $2.20 |
| Analyst Decision | Hold | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $4.43 | N/A |
| AVG Volume (30 Days) | 61.1K | ★ 77.0K |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 50.13 | ★ 3431.25 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $233,273,000.00 | $127,637.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.53 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.55 | $1.80 |
| 52 Week High | $6.40 | $113.80 |
| Indicator | CDLX | ADVB |
|---|---|---|
| Relative Strength Index (RSI) | 27.28 | 36.17 |
| Support Level | $0.85 | $1.80 |
| Resistance Level | $2.32 | $5.59 |
| Average True Range (ATR) | 0.19 | 0.53 |
| MACD | -0.01 | 0.17 |
| Stochastic Oscillator | 2.83 | 20.47 |
Cardlytics Inc is a commerce media platform that is designed to make commerce smarter and rewarding for everyone. At the core of its commerce media platform is the financial media network that it runs within its partners' digital channels, which includes online and mobile applications (the Cardlytics platform). Additionally, it operates an identity resolution platform that utilizes point-of-sale (POS) data, including product-level purchase data, to enable marketers to perform analytics and targeted loyalty marketing and also measure the impact of their marketing (the Bridg platform). It operates in three segments: the Cardlytics platform in the U.S.; the Cardlytics platform in the U.K.; and the Bridg platform. The majority of the revenue is derived from the Cardlytics platform.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.